QuidelOrtho Corporation

QDEL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-92.9M $-91.8M $-130.7M $-733.0M $-255.4M $-12.7M $-178.4M $-19.9M
Depreciation & Amortization $116.7M $112.9M $112.5M $112.1M $110.3M $107.1M $109.3M $113.1M
Depreciation — — — — — — — —
Amortization $49.0M $46.8M $45.6M $47.7M $47.9M $48.0M $47.9M $51.9M
Stock-Based Compensation $12.0M $10.7M $10.8M $10.7M $12.8M $11.6M $9.6M $12.3M
Net Cash from Operating Activities $-110.6M $-33.0M $131.9M $-45.5M $-46.8M $65.6M $63.7M $117.9M
Investing Activities
Capital Expenditures $25.5M $34.0M $45.3M $49.2M $37.5M $56.2M $47.2M $46.5M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-107.3M $-34.0M $-49.6M $-53.9M $-33.0M $-56.2M $-37.9M $-56.5M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $200.6M $37.6M $-11.1M $46.0M $103.3M $17.6M $-68.9M $-26.3M
Net Change in Cash $-17.0M $-29.4M $71.7M $-53.6M $24.5M $28.7M $-45.5M $36.5M
Free Cash Flow $-136.1M $-67.0M $86.6M $-94.7M $-84.3M $9.4M $16.5M $71.4M
← Newer Page 1 of 3 Older →